Home
Resources
Publications
Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): A Randomized, Double-Blind, Placebo-Controlled, 6-week Trial

Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): A Randomized, Double-Blind, Placebo-Controlled, 6-week Trial

C-H Lin, P-K Chen, S-H Wang, H-Y Lane

J Psychopharmacol. 2019 Aug;33(8):1030-1033.

PMID: 31113277

Abstract:

Objective:
Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD).
Methods:
In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0 mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD.
Results:
Two treatments showed similar safety and primary and secondary outcomes.
Conclusions:
Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP532321-A	Sodium benzoate		532-32-1	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: